Absci

Unlocking differentiated biology with generative AI

[Absci @abscibio]

In a recent Fortune feature, our Founder and CEO Sean McClain and Chief Medical Officer Ransi discuss how Absci’s AI-designed monoclonal antibody is moving closer to patients following the release of positive interim Phase 1 safety data. They also share our strategic path forward to accelerate clinical development and why the recent $100M underwritten offering backed by Eli Lilly signals growing industry validation for the prolactin receptor mechanism.

🗞️ Read the feature: https://t.co/M7M1USzOZj

[Absci @abscibio]

Absci Founder and CEO @SeanRMcClain has had a front-row seat driving the transformation of biotech. In his latest @TEDx talk, Sean discusses how the human body operates on a fixed energy budget, and how generative AI can design therapeutics that hold the key to redirecting that energy toward regenerative biology.

"What if you could take the energy that goes into degeneration—think autoimmune diseases, where the body attacks itself—and flip the switch to redirect or reallocate that energy into regeneration, where the body can heal itself?"

📌Watch the full TEDx talk "Can We Flip the Body's Regenerative Switch?" https://t.co/CWUIJR5bWN

[Absci @abscibio]

Our Founder and CEO, @SeanRMcClain, returned to the University of Arizona @UAZFrankeHonors to sit down with his former professor, Dean @JohnPollard, on the university’s It's an Honor Podcast. It’s an inspiring conversation on leading with curiosity, foundational mentorship shaping long-term success, and the programming biology with generative AI.

Listen to the podcast: • Apple • Spotify • Overcast • Pocket Casts • Amazon https://t.co/UU4WAVAMf9

[Absci @abscibio]

US soccer legend @landondonovan just shared his thoughts on Instagram about our ABS-201 program and clinical trial. See how he's partnering with absci for pattern hair loss research.

Interested in learning more or applying for the study?
📷 Check your eligibility at https://t.co/gDu1gV5EAJ

[Absci @abscibio]

Off-the-shelf AI models are powerful, but they often stumble when facing complex, real-world drug development challenges like antibody polyreactivity—one of the most common reasons promising candidates fail early.

Our latest research published in mAbs details how we used locally tuned in silico AI models to efficiently resolve antibody polyreactivity during drug development.

⚫ Reliable Ground Truth Data: We introduced Range Normalized Summation (RNS) scores derived from multi-concentration mAb ELISAs. Demonstrating exceptional reproducibility across different reagents and separate experiments, these scores provide the high-quality ground truth measurements required to build expandable datasets for modeling.

⚫The AI Bridge (Fine-Tuning PLMs): To translate this data into better antibody designs, we train AI specifically by fine-tuning Protein Language Models (PLMs) on localized sequence data. We demonstrate specialized tuning is required for efficiently inferring novel, low-, or non-polyreactive variants in some contexts, in this case driving a 66% success rate with just 18 attempts vs 0% for the top performing base model.

⚫ Transparency & Advancing the Field: Antibody sequences and associated in vitro polyreactivity scores are provided in the supplemental material for use in future benchmarking studies.

Read the full paper here: https://t.co/lvL5J1JCWI

[Absci @abscibio]

A big day for Absci

We're pleased to announce we priced a $100M underwritten offering, with participation from Eli Lilly & Company alongside leading financial investors: Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile, and a large investment management firm.

Proceeds will fund continued advancement of ABS-201™, our AI-designed anti-PRLR antibody, and expand our leadership in prolactin biology — a mechanism with a compelling, underexplored role across two large, underserved markets: androgenetic alopecia and endometriosis. Read the release here: https://t.co/nsWZTbIcOT

Earlier today, we also reported positive interim Phase 1 safety data from the HEADLINE™ trial of ABS-201, our AI-designed anti-PRLR antibody. Read the release here: https://t.co/HbE68r1Kyu

[Absci @abscibio]

We're excited to share positive interim safety data from our HEADLINE™ Phase 1/2a trial of ABS-201, our anti-PRLR antibody for androgenetic alopecia

Key Highlights: 
- Study medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) cohorts
- Estimated half-life of at least 65 days supports potential for ABS-201 targeted dosing interval of two or three injections over six-month period
- First multiple ascending dose (MAD) of ABS-201 in cohort of androgenetic alopecia participants has been initiated

It's a strong start for ABS-201, and we're looking forward to interim proof-of-concept data in the second half of 2026, with full PoC data in early 2027.

Read the full release: https://t.co/DnYm1XU2tx

[Absci @abscibio]

Absci's HEADLINE™ Phase 1/2a human clinical trial continues to progress in Australia under the guidance of renowned KOLs.

Our AI-designed anti-PRLR antibody, ABS-201 has the potential to introduce the first new mechanism of action for androgenetic alopecia (pattern hair loss) in nearly three decades. Recent translational human ex vivo scalp models demonstrated that ABS-201 effectively stimulates hair growth by regenerating the stem cell niche as well as promoting additional key growth modulators.

Learn more and see if you qualify: https://t.co/VFjLBE1FFb

[Absci @abscibio]

It started in a 400 sq. ft. basement lab and a deeply held belief that the future of health lies in merging human ingenuity with machine intelligence. Today, that belief blossomed into an industry-leading AI platform pioneering a new era of medicine.

Our Founder and CEO, @SeanRMcClain, will be taking the stage as a TEDxPortland Year 14 Speaker! Hear his vision for a world that moves beyond symptom management to engineering lifesaving medicines and cures.

Share this moment with us Saturday, April 11: https://t.co/Fwe6tlzyul

[AMD @AMD]

"AMD is helping Absci really push that frontier of AI drug discovery." - @Abscibio Founder and CEO, @SeanRMcClain shares a deeper dive into our collaboration to impact healthcare through AI.

[Absci @abscibio]

We’re excited to introduce Origin-1: a generative AI platform for de novo antibody design against "zero-prior" epitopes.

Origin-1 has been successfully validated against four targets: COL6A3, AZGP1, CHI3L2, and IL36RA

Key Highlights:
-Fewer than 100 design attempts per target
-Binding, developability, and ~100 nM functional potency confirmed across 5+ -orthogonal assays
-Atomic accuracy confirmed by cryo-EM

Our approach addresses a critical challenge in therapeutic discovery: designing antibodies for "zero-prior'"epitopes, which we define as target sites lacking structural data from reported antibody-antigen or protein-protein complexes involving the target.

To our knowledge, this is the first demonstration of de novo design of full-length monoclonal antibodies (mAbs) against "zero-prior" epitopes with atomically accurate complex structures and functional activity.

Read the preprint: https://t.co/vG7Ll7hcRI
Access our data: https://t.co/1s8cAeW5MS

[AMD @AMD]

Advanced Insights: Season 2 Rewind

Hear Advanced Insights host Mark Papermaster and @SeanRMcClain, Founder and CEO of @abscibio, dive into how AI is completely disrupting the drug discovery process.

With AI applications, biotechnology organizations, and eventually big pharma companies, can drastically reduce the time and cost investments required to bring groundbreaking drugs to market.

Check out the full episode here https://t.co/PvTsyJwlsM

[AMD @AMD]

Advanced Insights: Season 2 Rewind

Join AMD CTO Mark Papermaster and Dan Rabinovitsj, VP of Infrastructure at @Meta, as they discuss the complexity of deploying AI at the edge, and the importance of reliability.

Watch the full episode here: https://t.co/HR9N1KOQDy

[AMD @AMD]

During the #CES2026 Keynote address, @LisaSu was joined by @Abscibio CEO @SeanRMcClain, @Illumina CEO Jacob Thaysen, and @AstraZeneca Head of Molecular AI, Ola Engkvist, in a fireside chat to discuss applying AI to real-world healthcare challenges.

[Meghan Grady @MegRaeGrady]

Work and personal life just collided in a surprising & cool way. In @LisaSu's keynote at #CES2026, @s@seanmcclain shared the work Absci is doing to advance drug development using generative AI, specifically for #Endometriosis & Alopecia.

3 weeks ago I had surgery for Endo. Currently there is no cure. The procedure I had is one of a few options to manage symptoms.

Thank you @abscibio for your work in this space, and thank you #AMD for supporting it! 🙏

https://t.co/BZJQHfwX5i

[Absci @abscibio]

Proud to work with @landondonovan to shine a light on the significant impact of hair loss and the need for better therapies for patients.

Learn more about Absci's research in AGA at our KOL Seminar:
https://t.co/dYTMyQjBNa

[Landon Donovan @landondonovan]

Hair update: So many of you have reached out wanting to know what the latest is for hair-loss.

I've teamed up with Absci who is doing really incredible clinical research to completely change hair-loss forever.

@abscibio @SeanRMcClain

[Landon Donovan @landondonovan]

Hair update: So many of you have reached out wanting to know what the latest is for hair-loss.

I've teamed up with Absci who is doing really incredible clinical research to completely change hair-loss forever.

@abscibio @SeanRMcClain

[ARK Invest @ARKInvest]

From AI-designed HIV antibodies to regenerative treatments for hair loss, @abscibio's @SeanRMcClain joins @CathieDWood and @wintonARK on FYI to share how generative AI is transforming drug discovery.

https://t.co/Hvz5Rpt4Wu